| Literature DB >> 35356244 |
Feiyu Xie1,2, Mina Wang1,3, Yixin Su2, Kunmin Xiao1,2,4, Xuelei Chu2, Sidan Long1,2, Linlu Li1,2, Xin Zhang1,2, Peng Xue2, Shijie Zhu2.
Abstract
Background: Lung metastasis of malignant tumor signifies worse prognosis and immensely deteriorates patients' life quality. Spatholobi Caulis (SC) has been reported to reduce lung metastasis, but the mechanism remains elusive.Entities:
Year: 2022 PMID: 35356244 PMCID: PMC8959948 DOI: 10.1155/2022/1620539
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Active components of SC.
| Mol ID | Molecule name | OB% | DL |
|---|---|---|---|
| MOL000296 | Hederagenin | 36.91 | 0.75 |
| MOL000033 | (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol | 36.23 | 0.78 |
| MOL000358 | Beta-sitosterol | 36.91 | 0.75 |
| MOL000392 | Formononetin | 69.67 | 0.21 |
| MOL000417 | Calycosin | 47.75 | 0.24 |
| MOL000449 | Stigmasterol | 43.83 | 0.76 |
| MOL000461 | 3,7-Dihydroxy-6-methoxy-dihydroflavonol | 43.8 | 0.26 |
| MOL000468 | 8-o-Methylreyusi | 70.32 | 0.27 |
| MOL000469 | 3-Hydroxystigmast-5-en-7-one | 40.93 | 0.78 |
| MOL000470 | 8-C- | 35.54 | 0.66 |
| MOL000471 | Aloe-emodin | 83.38 | 0.24 |
| MOL000483 | (Z)-3-(4-hydroxy-3-methoxy-phenyl)-N-[2-(4-hydroxyphenyl) ethyl]acrylamide | 118.35 | 0.26 |
| MOL000490 | Petunidin | 30.05 | 0.31 |
| MOL000491 | Angelicin | 37.5 | 0.66 |
| MOL000492 | Catechin | 54.83 | 0.24 |
| MOL000493 | Campesterol | 37.58 | 0.71 |
| MOL000497 | Licochalcone a | 40.79 | 0.29 |
| MOL000500 | Vestitol | 74.66 | 0.21 |
| MOL000501 | Consume close grain | 68.12 | 0.27 |
| MOL000502 | Cajanin | 68.8 | 0.27 |
| MOL000503 | Medicagol | 57.49 | 0.6 |
| MOL000506 | Lupinidine | 61.89 | 0.21 |
| MOL000507 | Psi-baptigenin | 70.12 | 0.31 |
| MOL000006 | Luteolin | 36.16 | 0.25 |
OB: oral bioavailability; DL: drug-likeness.
Figure 1(a) Intersection targets of SC and secondary malignant neoplasm of lung. (b) PPI network of intersection targets. (c) PPI network of hub targets.
Figure 2GO enrichment analysis and KEGG pathway analysis of the intersection targets: (a) biological process; (b) molecular function; (c) cellular component; (d) Kyoto Encyclopedia of Genes and Genomes pathway analysis.
Figure 3Network of SC-active components-intersection targets-KEGG pathway.
Figure 4Molecular docking of hub targets and active components: (a) RELA-Aloe-emodin; (b) JUN-8-C-α-L-arabinosylluteolin; (c) MAPK1-Calycosin; (d) MAPK14-Catechin; (e) STAT3-Medicago; (f) IL-4-Vestitol; (g) ESR1-Catechin; and (h) TP53-Hederagenin.